Infusion of angiotensin-(1–7) reduces glomerulosclerosis through counteracting angiotensin II in experimental glomerulonephritis
- 1 March 2010
- journal article
- research article
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 298 (3), F579-F588
- https://doi.org/10.1152/ajprenal.00548.2009
Abstract
Recent identification of a counterregulatory axis of the renin-angiotensin system, called angiotensin-converting enzyme 2-angiotensin-(1–7) [ANG-(1–7)]-Mas receptor, may offer new targets for the treatment of renal fibrosis. We hypothesized that therapy with ANG-(1–7) would improve glomerulosclerosis through counteracting ANG II in experimental glomerulonephritis. Disease was induced in rats with the monoclonal anti-Thy-1 antibody, OX-7. Based on a three-dose pilot study, 576 μg·kg−1·day−1 ANG-(1–7) was continuously infused from day 1 using osmotic pumps. Measures of glomerulosclerosis include semiquantitative scoring of matrix proteins stained for periodic acid Schiff, collagen I, and fibronectin EDA+ (FN). ANG-(1–7) treatment reduced disease-induced increases in proteinuria by 75%, glomerular periodic acid Schiff staining by 48%, collagen I by 24%, and FN by 25%. The dramatic increases in transforming growth factor-β1, plasminogen activator inhibitor-1, FN, and collagen I mRNAs seen in disease control animals compared with normal rats were all significantly reduced by ANG-(1–7) administration ( P < 0.05). These observations support our hypothesis that ANG-(1–7) has therapeutic potential for reversing glomerulosclerosis. Several results suggest ANG-(1–7) acts by counteracting ANG II effects: 1) renin expression in ANG-(1–7)-treated rats was dramatically increased as it is with ANG II blockade therapy; and 2) in vitro data indicate that ANG II-induced increases in mesangial cell proliferation and plasminogen activator inhibitor-1 overexpression are inhibited by ANG-(1–7) via its binding to a specific receptor known as Mas.Keywords
This publication has 46 references indexed in Scilit:
- Angiotensin I Is Largely Converted to Angiotensin (1-7) and Angiotensin (2-10) by Isolated Rat GlomeruliHypertension, 2009
- Angiotensin-(1-7) and Its Effects in the KidneyThe Scientific World Journal, 2009
- Endogenous angiotensin-(1-7) reduces cardiac ischemia-induced dysfunction in diabetic hypertensive ratsPharmacological Research, 2008
- A PAI-1 Mutant, PAI-1R, Slows Progression of Diabetic NephropathyJournal of the American Society of Nephrology, 2008
- Emerging Evidence for a Functional Angiotensin-Converting Enzyme 2-Angiotensin-(1-7)-Mas Receptor AxisHypertension, 2007
- Isoproterenol-induced impairment of heart function and remodeling are attenuated by the nonpeptide angiotensin-(1-7) analogue AVE 0991Life Sciences, 2007
- Angiotensin-(1–7) and the renin–angiotensin systemCurrent Opinion in Nephrology and Hypertension, 2007
- Impairment of In Vitro and In Vivo Heart Function in Angiotensin-(1-7) Receptor Mas Knockout MiceHypertension, 2006
- Combining TGF-β inhibition and angiotensin II blockade results in enhanced antifibrotic effectKidney International, 2004
- Transforming Growth Factor β in Hypertensives With Cardiorenal DamageHypertension, 2000